The full content of Annals is available to subscribers

Background: Repaglinide is a short-acting, orally administered drug used to control postprandial hyperglycemia in patients with type 2 diabetes mellitus. Although chemically unrelated to the sulphonylureas, repaglinide acts similarly by stimulating release of insulin from the pancreas β cells. The drug is metabolized in the liver to inactive metabolites, mainly through the CYP3A4 enzyme of the P450 cytochrome system, and is eliminated by the biliary–fecal route (1). Repaglinide is considered a safe agent; adverse events are mild to moderate and are similar to those associated with sulphonylureas. The most frequently reported side effects include hypoglycemia, upper respiratory tract inflammation, headache, nausea, diarrhea, vomiting, and dyspepsia (2).